Colorectal cancer

Molecular characterisation of gastrointestinal tumours through genomic, transcriptomic and proteomic analysis (R. Salazar, V. Moreno).
Construction of molecular signatures for predicting colorectal cancer prognosis (R. Salazar).
Predictions of therapeutic response based on molecular tumour detection and subtype classification (R. Salazar)
New experimental therapeutic strategies to overcome resistance in colorectal cancer treatment (R. Salazar).
Research, evaluation and validation of new diagnostic biomarkers in colorectal cancer (V. Moreno).
Genetic and epigenetic determinants of susceptibility to CRC and chemotherapy toxicity (V. Moreno).
Improvement in cancer precision medication and biomarker identification using computational analysis and large-scale integration of molecular data. (X. Solé).
Stratification of CRC patients based on molecular characteristics and the level of immune-cell infiltration of their tumours (C. Santos andR. Sanz-Pamplona).
Microbiome-host interactions and colorectal cancer (V. Pimenoff, M. Obon, V. Moreno).
Prognostic and predictive values of circulating tumour DNA in metastatic colorectal cancer (C. Santos).

• Carreras Torres,R;Galvan Femenia,I;Farre,X;Cortes,B;Diez Obrero,V;Carreras,A;Moratalla Navarro,F et al, Multiomic integration analysis identifies atherogenic metabolites mediating between novel immune genes and cardiovascular risk, Genome Med., 2024;16(1):122-122, doi:10.1186/s13073-024-01397-2
• Laskar,RS;Qu,C;Huyghe,JR;Harrison,T;Hayes,RB;Cao,Y;Campbell,PT et al, Genome-wide association studies and Mendelian randomization analyses provide insights into the causes of early-onset colorectal cancer, Ann. Oncol., 2024;35(6):523-536, doi:10.1016/j.annonc.2024.02.008
• Moreno Cabrera,JM;Feliubadaló,L;Pineda,M;Prada Dacasa,P;Ramos Muntada,M;Del Valle,J;Brunet,J et al, SpadaHC: a database to improve the classification of variants in hereditary cancer genes in the Spanish population, Database, 2024;2024doi:10.1093/database/baae055
• Obón Santacana,M;Moratalla Navarro,F;Guinó,E;Carreras Torres,R;Díez Obrero,V;Bars Cortina,D;Ibáñez Sanz,G et al, Diet Impacts on Gene Expression in Healthy Colon Tissue: Insights from the BarcUVa-Seq Study, Nutrients, 2024;16(18):doi:10.3390/nu16183131
• Ramon,E;Obón Santacana,M;Khannous Lleiffe,O;Saus,E;Gabaldón,T;Guinó,E;Bars Cortina,D et al, Performance of a Shotgun Prediction Model for Colorectal Cancer When Using 16S rRNA Sequencing Data, Int J Mol Sci, 2024;25(2):doi:10.3390/ijms25021181

• PID2023-151570OB-I00. Herencia epigenética intergeneracional en humanos: determinantes y contribución a la heredabilidad desconocida y al riesgo del cáncer colorrectal. Ministerio de Ciencia e Innovación. Budget: 337.500€. 2024-2028. PI: MORENO AGUADO, VICTOR RAUL.
• TRNSC213877MORE/AC22/00021. TANGERINE: Artificial-intelligence-based end-to-end prediction of cancer immunotherapy response. Instituto de Salud Carlos III (ISCIII)/Asociación Española Contra el Cáncer (AECC). Budget: 296.341€. 2022-2026. PI: MORENO AGUADO, VICTOR RAUL.
• AC21_2/00013 // PERME212445MORE. IMAGene: Epigenomic and machine learning models to predict pancreatic cancer: development of a new algorithm to integrate clinical, omics, DNA methylation biomarkers and environmental data for early detection of pancreatic cancer in high-risk individuals. Instituto de Salud Carlos III (ISCIII)/Asociación Española Contra el Cáncer (AECC). Budget: 304.687,96€. 2022-2025. PI: MORENO AGUADO, VICTOR RAUL.
• FORT23/00032. Smart Health Community (SHC), promoviendo la medicina basada en el valor. Instituto de Salud Carlos III. Budget: 416.724€. 2024-2027. PI: MORENO AGUADO, VICTOR RAUL.
• GCTRA18022MORE. Genetic and metabolomics screening towards the precision medicine in cancer prevention. Asociación Española Contra el Cáncer (AECC). Budget: 500.000€. 2018-2024. PI: MORENO AGUADO, VICTOR RAUL.

Participation in international consortiums: MOTRICOLOR (Molecularly guided trials with specific treatment strategies in patients with advanced newly molecular defined subtypes of colorectal cancer) and FIGI (Using functional genomics to inform gene environment interactions for CRC).
Colonomics as a platform for biomarker discovery and characterisation of CRC.
Clinical validation of ColoPrint®, a phase II prognostic genetic signature and new consensus on molecular subtype classification (CMS 1-4)